Body fat in men with prolactinoma.
OBJECTIVE
(a) To evaluate body fat in men with prolactinoma and healthy controls, using whole body dual energy x-ray absorptiometry (DXA), and (b) to correlate DXA results with anthropometry and clinical aspects of male prolactinomas.


METHODS
A cross-sectional study was performed in two University referral centers. Eleven newly-diagnosed men with prolactinoma and 9 with normal PRL levels due to dopamine agonist treatment were submitted to DXA and blood analysis (PRL, testosterone, dihydrotestosterone, estradiol, and SHBG) by the time of their clinical evaluation. They were compared with 14 control men of similar age and body mass index distribution.


RESULTS
Newly-diagnosed men with prolactinoma had higher fat percentage in the arms and the total body, when compared with patients treated with dopamine agonists and controls. The former group also presented higher fat percentage in the legs than the controls. Truncal fat percentage of the newly-diagnosed patients was lower than the dopamine agonist treated group. The 3 groups had similar android and gynoid fat contents. Fat percentage of the 6 sites correlated with PRL, testosterone, and dihydrotestosterone levels.


CONCLUSIONS
Newly-diagnosed men with prolactinomas had higher body fat content. Body fat was linked to disease control, especially to the PRL and androgen levels. Consequently, adequate control of hyperprolactinemia should be pursued in order to reduce the risk of obesity and its metabolic complications in men with prolactinoma.
Naliato
E C O
EC
Division of Endocrinology, Department of Internal Medicine, Federal University of Rio de Janeiro (UFRJ), Hyperprolactinemia Unit, Clementino Fraga Filho University Hospital (HUCFF), Rio de Janeiro, Brazil. erikanaliato@uol.com.br
Violante
A H D
AH
Gaccione
M
M
Caldas
D
D
Lamounier Filho
A
A
Loureiro
C R
CR
Fontes
R
R
Schrank
Y
Y
Costa
F S R
FS
Colao
A
A
D015502:Absorptiometry, Photon; D000273:Adipose Tissue / Q000473:pathology*; D000328:Adult; D000077465:Cabergoline; D003430:Cross-Sectional Studies; D018491:Dopamine Agonists / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015175:Prolactinoma / Q000188:drug therapy / Q000473:pathology*
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline